findmyKOL

Christopher Yasenchak, MD

Basic profile

Willamette Valley Cancer Institute and Research Center

ORCIDNPI
RegionEugene, OR · WestSpecialtyHematology / OncologyFocusOncology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Christopher Yasenchak is an Oncology physician affiliated with Willamette Valley Cancer Institute and Research Center. OpenAlex indexes 95 publications with 1,039 citations (h-index 16).

Overview

Scholarship

indexed output and impact (OpenAlex)
95publications

Distinct works indexed by OpenAlex, matched via ORCID.

1,039citations

Total citations across indexed works.

16h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
9companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

9 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    46.3%
    Iron, parenteral preparations24%
    Ferric carboxymaltose100%
    Part B, office-administered12 patients
    Erythropoiesis-stimulating Agent22.2%
    Darbepoetin alfa100%
    Part B, office-administered11 patients

    + 1 more class in this area

  • Cancer & immunology

    36.2%
    PD-1 inhibitor28.1%
    Pembrolizumab53%Nivolumab47%
    Part B, office-administered14 patients
    Microtubule Inhibitor6.7%
    Paclitaxel100%
    Part B, office-administered11 patients

    + 9 more classes in this area

  • Metabolism & gastrointestinal

    14.3%
    Substance P/Neurokinin-1 Receptor Antagonist11.6%
    Aprepitant100%
    Part B, office-administered21 patients
    Serotonin-3 Receptor Antagonist2.5%
    Palonosetron hcl55%Granisetron hydrochloride40%Ondansetron Hcl5%
    Part D + Part B34 patients

    + 3 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”